Kool-Aid

Meeami Unveils Innovative AI-Powered Background Noise Suppression Solutions for Enhanced Audio Quality on Cadence Tensilica HiFi DSP Family

Retrieved on: 
Wednesday, December 20, 2023

MILPITAS, Calif., Dec. 20, 2023 /PRNewswire-PRWeb/ -- Meeami Technologies (Meeami®), a pioneer and leader in Audio AI, Noise Cancellation, Speaker ID and Spatial Audio, announced the availability of its AI based, and low footprint background noise suppression embedded solutions for the Cadence Tensilica HiFi DSP family.

Key Points: 
  • Meeami Technologies pioneers Audio AI, unveiling low-footprint noise suppression solutions for Cadence Tensilica HiFi DSPs.
  • These solutions, optimized for individual HiFi DSP models, underscore the versatility and superior performance of the HiFi DSP family.
  • The collaboration leverages Cadence's DSP strengths—optimized audio processing, lower power consumption—for Meeami's advanced noise suppression, enhancing user experiences across voice-controlled devices and audio applications.
  • MILPITAS, Calif., Dec. 20, 2023 /PRNewswire-PRWeb/ -- Meeami Technologies (Meeami®), a pioneer and leader in Audio AI, Noise Cancellation, Speaker ID and Spatial Audio, announced the availability of its AI based, and low footprint background noise suppression embedded solutions for the Cadence Tensilica HiFi DSP family.

Medicare Advantage vs. Original Medicare: Which is best for you?

Retrieved on: 
Wednesday, November 15, 2023

Minneapolis, MN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- With Medicare open enrollment underway, it’s helpful for consumers to understand the difference between Original Medicare and Medicare Advantage.

Key Points: 
  • Minneapolis, MN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- With Medicare open enrollment underway, it’s helpful for consumers to understand the difference between Original Medicare and Medicare Advantage.
  • During the open enrollment period, millions of Medicare enrollees can :
    Switch from Original Medicare to Medicare Advantage, or vice versa.
  • Here are a few things to consider when deciding between Original Medicare versus Medicare Advantage, or pairing Original Medicare with a Medigap or Part D plan.
  • Prescription drug costs: Most Medicare Advantage plans include Medicare Part D drug coverage, but if you’re considering a Medicare Advantage plan, it’s a good idea to confirm and make sure.

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 9, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.
  • The management team will also host one-on-one investor meetings at the conferences.
  • Event: Jefferies London Healthcare Conference in London, UK
    Time: Company Presentation at 5:00 a.m.
  • It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients.

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer

Retrieved on: 
Thursday, December 14, 2023

High-risk neuroblastoma is a challenging disease, with a high mortality rate driven primarily by the risk of relapse after achieving remission.

Key Points: 
  • High-risk neuroblastoma is a challenging disease, with a high mortality rate driven primarily by the risk of relapse after achieving remission.
  • US WorldMeds partnered with the Beat Childhood Cancer Research Consortium at Penn State University, which conducted the preclinical and clinical research to help advance this vital therapy.
  • The Consortium represents a group of over 50 hospitals that offer collaboration through a network of childhood cancer clinical trials.
  • “We are thankful for the dedication of our partners, specifically the Beat Childhood Cancer Research Consortium, who work tirelessly to improve treatment outcomes for pediatric cancer patients.

Zepp Health Celebrates 10 Years of Innovation with a Purpose-Led Brand Refresh and Expanded Wellness Healthcare Solutions

Retrieved on: 
Wednesday, December 6, 2023

Zepp Health Corporation ("Zepp Health") (NYSE: ZEPP), a global leader in smart wearables and health technology, commemorates its 10th anniversary with a brand refresh.

Key Points: 
  • Zepp Health Corporation ("Zepp Health") (NYSE: ZEPP), a global leader in smart wearables and health technology, commemorates its 10th anniversary with a brand refresh.
  • The unveiling of a refined brand vision, mission, and visual identity signifies the company's evolution from a hardware brand to a wellness and health technology brand, embracing a philosophy of empowerment and support for individuals on their health and wellness journeys.
  • As Zepp Health marks a decade of innovation, the brand refresh reaffirms its dedication to shaping the future of integrated health and wellness solutions.
  • With a renewed focus on empowerment and inspiration, Zepp Health remains committed to providing thoughtful solutions on the path to greater and more informed well-being.

Advanced Bionics Extends Marvel CI Product Offering With Remote Programming and Expanded Linked Two-ear Solutions

Retrieved on: 
Monday, December 4, 2023

Remote Programming is another step towards improving accessibility for hearing healthcare for as many people as possible.

Key Points: 
  • Remote Programming is another step towards improving accessibility for hearing healthcare for as many people as possible.
  • Now AB’s Marvel will also be the only CI system with a CROS (Contralateral Routing of Signal) device.
  • Together with a pair of Marvel CI sound processors, or a bimodal pairing with Marvel CI and a Phonak Link M hearing aid, the introduction of CROS makes Marvel the only CI system with linked bilateral, bimodal, and CROS configurations.
  • “Since its introduction in 2020, Marvel CI has redefined hearing performance with cochlear implants," said Victoria E.Carr-Brendel, Ph.D., GVP, Sonova Group and President of Advanced Bionics.

For Acclaimed Baroque Flutist Stephen Schultz, Classic Rock Prompted a Journey to Better Hearing -- and Widex MOMENT Sheer Hearing Aids

Retrieved on: 
Thursday, December 14, 2023

Decades into a celebrated career as a musician and educator, renowned Baroque flutist Stephen Schultz needed hearing aids.

Key Points: 
  • Decades into a celebrated career as a musician and educator, renowned Baroque flutist Stephen Schultz needed hearing aids.
  • Facing a choice between hearing aids and an operation that might fix the tiny bones in his ears, Schultz waited.
  • And that's the journey that led Schultz to the Widex Moment Sheer hearing aids he wears today.
  • "Yes, hearing aids amplify sound, but really good ones like my Widex Moment Sheer hearing aids let you hear the rich palate that you'd normally miss," he says.

Global Wearable Healthcare Devices Market to Accrue $146.89 Billion by 2030, Recording a Strong CAGR of 27.40%, with North America Leading the Market Due to Robust Healthcare Infrastructure, Projects Kings Research

Retrieved on: 
Tuesday, December 12, 2023

Wearable healthcare devices are becoming increasingly prevalent as individuals seek to proactively manage their health and gain immediate insights into their well-being.

Key Points: 
  • Wearable healthcare devices are becoming increasingly prevalent as individuals seek to proactively manage their health and gain immediate insights into their well-being.
  • Their ability to provide continuous monitoring and early detection of health problems presents a promising opportunity for revolutionizing healthcare.
  • Major companies operating in the wearable healthcare devices market are prioritizing partnerships in order to stay ahead of the competition.
  • Prominent players in the global wearable healthcare devices market include:

Global Wearable Healthcare Devices Market to Accrue $146.89 Billion by 2030, Recording a Strong CAGR of 27.40%, with North America Leading the Market Due to Robust Healthcare Infrastructure, Projects Kings Research

Retrieved on: 
Tuesday, December 12, 2023

Wearable healthcare devices are becoming increasingly prevalent as individuals seek to proactively manage their health and gain immediate insights into their well-being.

Key Points: 
  • Wearable healthcare devices are becoming increasingly prevalent as individuals seek to proactively manage their health and gain immediate insights into their well-being.
  • Their ability to provide continuous monitoring and early detection of health problems presents a promising opportunity for revolutionizing healthcare.
  • Major companies operating in the wearable healthcare devices market are prioritizing partnerships in order to stay ahead of the competition.
  • Prominent players in the global wearable healthcare devices market include:

Nokia and Celesta Capital Announce Major Strategic Partnership for Acceleration of Deep Technologies

Retrieved on: 
Monday, December 11, 2023

SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Nokia and Celesta Capital today announced a long-term strategic partnership to accelerate the commercialization of deep technologies invented by Nokia Bell Labs, including advanced communications, AI and deep learning, next-generation semiconductor fabrication, sensors, and quantum computing. Celesta Capital will help cultivate and invest in key technologies incubated and developed within Nokia Bell Labs, to form commercially viable, independent venture-backed companies. The new partnership unites Nokia Bell Labs' robust IP portfolio and research prowess with Celesta Capital's unique expertise as a global deep tech investor and business builder.   

Key Points: 
  • SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Nokia and Celesta Capital today announced a long-term strategic partnership to accelerate the commercialization of deep technologies invented by Nokia Bell Labs, including advanced communications, AI and deep learning, next-generation semiconductor fabrication, sensors, and quantum computing.
  • Celesta Capital will help cultivate and invest in key technologies incubated and developed within Nokia Bell Labs, to form commercially viable, independent venture-backed companies.
  • The new partnership unites Nokia Bell Labs' robust IP portfolio and research prowess with Celesta Capital's unique expertise as a global deep tech investor and business builder.
  • The core focus of the partnership will work to incorporate technology developed by Nokia Bell Labs into newly created companies.